| Literature DB >> 30221551 |
Priscilla de Graaff1,2, Coen Govers2, Harry J Wichers2, Reno Debets1.
Abstract
INTRODUCTION: Adoptive T-cell treatments of solid cancers have evolved into a robust therapy with objective response rates surpassing those of standardized treatments. Unfortunately, only a limited fraction of patients shows durable responses, which is considered to be due to a T cell-suppressive tumor microenvironment (TME). Here we argue that naturally occurring β-glucans can enable reversion of such T cell suppression by engaging innate immune cells and enhancing numbers and function of lymphocyte effectors. AREAS COVERED: This review summarizes timely reports with respect to absorption, trafficking and immune stimulatory effects of β-glucans, particularly in relation to innate immune cells. Furthermore, we list effects toward well-being and immune functions in healthy subjects as well as cancer patients treated with orally administered β-glucans, extended with effects of β-glucan treatments in mouse cancer models. EXPERT OPINION: Beta-glucans, when present in food and following uptake in the proximal gut, stimulate immune cells present in gut-associated lymphoid tissue and initiate highly conserved pro-inflammatory pathways. When tested in mouse cancer models, β-glucans result in better control of tumor growth and shift the TME toward a T cell-sensitive environment. Along these lines, we advocate that intake of β-glucans provides an accessible and immune-potentiating adjuvant when combined with adoptive T-cell treatments of cancer.Entities:
Keywords: Adoptive T cell therapy; innate immunity; pattern recognition receptors; β-glucans
Mesh:
Substances:
Year: 2018 PMID: 30221551 DOI: 10.1080/14712598.2018.1523392
Source DB: PubMed Journal: Expert Opin Biol Ther ISSN: 1471-2598 Impact factor: 4.388